DelveInsight launched a new report on Neuropathic Pain – Epidemiology Forecast to 2030
Some of the key facts of the report:
- In the UK, eight per cent of the general population experience neuropathic pain.
- The prevalence of chronic pain to be 16.6% and the prevalence of neuropathic pain was 3.2%.
- The United States has the highest percentage of prevalent diagnosed and treated patients.
“It was observed that 67.5% of the patients with neuropathic pain were in the 65–74 age group.”
The primary goals of neuropathic pain treatment are to manage the pain as much as possible and to minimize the negative side-effects.
There are various neuropathic pain treatments available, and often it is a ‘trial and error’ process to find the best option for a person. Regular painkillers such as nonsteroidal anti-inflammatory drugs or NSAIDs (for example ibuprofen, aspirin and paracetamol) are usually not effective for neuropathic pain.
Medications used for neuropathic pain treatment include over-the-counter analgesics, anticonvulsants, tricyclic antidepressants (TCAs), topical anaesthetic agents, nonsteroidal anti-inflammatory drugs (NSAIDs), antiarrhythmics, narcotic analgesics, and opioids.
Combination therapies are often used in patients with neuropathic pain who have either failed to have a response or only had a partial response to monotherapy. In theory, utilizing lower doses of different classes of drugs may help alleviate or prevent adverse drug effects that are seen with higher doses of monotherapy. Studies have focused on the use of combination therapies and have found mixed results. A meta-analysis of two studies did find that a combination of gabapentin with an opioid was superior to monotherapy (or placebo), but the combination of the two medications was associated with higher drop-out rates due to adverse effects. A large study that focused on comparing duloxetine and pregabalin at high doses as monotherapy to lower doses in combination did not show any difference in efficacy or side effects. Researchers continue to seek new treatments for neuropathic pain. There are new voltage-gated sodium channel blockers that are receptor-specific and may have less risk of cardiac, motor and central nervous system adverse effects. A review of stem cell therapy focused on preclinical data suggested that adult stem cell therapy in patients with neuropathic pain showed positive effects, with peripheral appearing to be more responsive than central neuropathic pain. Studies that focus on genetics and subgrouping patients based on their phenotypes may play an essential role in the future of personalized pain management for neuropathic pain.
Request for sample pages : https://www.delveinsight.com/sample-request/neuropathic-pain-epidemiology-forecast
Scope of the Report
- The Neuropathic Pain report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
- The Neuropathic Pain Epidemiology Report and Model provide an overview of the risk factors and global trends of Neuropathic Pain in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
- The report provides insight about the historical and forecasted patient pool of Neuropathic Pain in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
- The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
- The report assesses the disease risk and burden and highlights the unmet needs of Neuropathic Pain
- The report provides the segmentation of the Neuropathic Pain epidemiology
KOL- Views
We interview, KOLs and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.
Key Questions Answered
- What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Neuropathic Pain?
- What are the key findings pertaining to the Neuropathic Pain epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
- What would be the total number of patients of Neuropathic Pain across the 7MM during the forecast period (2017-2030)?
- Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
- At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
- What is the disease risk, burden and unmet needs of the Neuropathic Pain?
- What are the currently available treatments of Neuropathic Pain?
Request for sample pages : https://www.delveinsight.com/sample-request/neuropathic-pain-epidemiology-forecast
Reasons to buy
- The Neuropathic Pain Epidemiology report will allow the user to –
- Develop business strategies by understanding the trends shaping and driving the global Neuropathic Pain market
- Quantify patient populations in the global Neuropathic Pain market to improve product design, pricing, and launch plans
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Neuropathic Pain therapeutics in each of the markets covered
- Understand the magnitude of Neuropathic Pain population by its epidemiology
- The Neuropathic Pain Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources
Key Assessments
- Patient Segmentation
- Disease Risk and Burden
- Risk of disease by the segmentation
- Factors driving growth in a specific patient population
Related Reports :
Neuropathic Pain – Pipeline Insights, 2020
The Neuropathic Pain report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Neuropathic Pain across the complete product development cycle, including all clinical and nonclinical stages.
Neuropathic Pain- Market Insight, Epidemiology and Market Forecast -2030
The Neuropathic Pain market report provides current treatment practices, emerging drugs, Neuropathic Pain market share of the individual therapies, current and forecasted Neuropathic Pain market Size from 2017 to 2030 segmented by seven major markets.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NEVADA 89107
Country: United States
Website: https://www.delveinsight.com/